Physician profile
Mark S Weissig
NPI 1649266032
$4,869.27
in general payments reported to CMS, 2019-2025
13 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $662 · 2021: $460 · 2022: $530 · 2023: $639 · 2024: $346 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,818.64 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,238.03 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,068.81 | 2019-2025 | Breztri, Airsupra, Symbicort |
| Genentech USA, INC. | $218.64 | 2019-2020 | |
| Insmed, INC. | $203.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $66.88 | 2021-2023 | Eliquis |
| Philips North America LLC | $58.46 | 2019 | |
| Amgen INC. | $48.84 | 2019 | |
| Csl Behring | $40.54 | 2019-2020 | |
| Grifols USA, LLC | $35.11 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.67 | 2022 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| United Therapeutics Corporation | $19.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weissig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.